Skip to main
DERM
DERM logo

DERM Stock Forecast & Price Target

DERM Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Journey Medical Corp has demonstrated significant growth in payer access, expanding coverage from approximately 30% of commercial lives to around 65% within a two-month period, which translates to over 100 million lives enhanced by their product offerings. Additionally, prescriber adoption has seen substantial increases, rising from about 660 in the first quarter to over 1,800 by the second quarter, indicating strong market traction and acceptance of the company's products. Furthermore, the enduring brand value of key products like Accutane fosters consumer retention and market share stability, further supporting a positive outlook for the company's financial prospects.

Bears say

Journey Medical Corp has experienced a significant decline in prescription volume for its key product, Accutane, with first-quarter 2025 prescriptions falling to approximately 66,000 from 93,000 in the same period of 2024, indicating potential challenges in market demand. Additionally, the company's future earnings before interest, taxes, depreciation, and amortization (EBITDA) may be adversely affected by slower-than-anticipated uptake of its new product, Emrosi, coupled with potential reimbursement barriers from payers. There are also multiple risks associated with its operations, including competitive pressures from both branded and generic treatments, regulatory uncertainties, and the possibility of increased cash burn that could impact financial stability going forward.

DERM has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Journey Medical Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Journey Medical Corp (DERM) Forecast

Analysts have given DERM a Strong Buy based on their latest research and market trends.

According to 3 analysts, DERM has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Journey Medical Corp (DERM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.